Paris, France, May 26, 2023 – 6:00 p.m. CEST – ACTICOR BIOTECH (FR0014005OJ5 – ALACT), a clinical-stage biopharmaceutical company developing glenzocimab, an innovative drug for the treatment of cardiovascular emergencies, including ischemic stroke, announces that it has participated in the European Stroke Organization Conference (ESOC) 2023 on May 24, 25 and 26, 2023 in Munich, Germany.
Sophie BINAY, Deputy Managing Director and Scientific Director, declares: “The posters presented at this essential conference for stroke research and the holding of our Scientific Council and a round table with the participation of many investigators and partners, underline the important role that Acticor Biotech plays in this ecosystem and the urgent need for new innovative treatments in stroke. We are continuing our efforts every day to develop our drug candidate glenzocimab in order to respond to the important medical challenge represented by stroke, but more generally cardiovascular emergencies. »
To receive all of Acticor Biotech’s financial information in real time, send a request by email to [email protected]